文献速递肝病

ARRB1通过促进GDF15成熟抑制非酒精性脂肪性肝炎进展

ARRB1 inhibits non-alcoholic steatohepatitis progression by promoting GDF15 maturation.
PubMed 文献 · J Hepatol · 2019-12-16

研究探讨β-抑制蛋白1(ARRB1)在非酒精性脂肪性肝炎(NASH)进展中的作用。NASH患者肝组织ARRB1表达降低,Arrb1缺失加速高脂饮食或MCD饮食小鼠的脂肪性肝炎进展;ARRB1与GDF15前体相互作用并促进其向高尔基体转运及成熟,重组GDF15可消除Arrb1缺失导致的脂质积累。结论:ARRB1是NASH的潜在治疗靶点。

要点

  • NASH患者及小鼠模型肝组织中ARRB1表达降低。
  • ARRB1促进GDF15前体向高尔基体转运并成熟。
  • 重组GDF15可逆转Arrb1缺失引起的脂质积累。

核心结论

  • ARRB1通过促进GDF15向高尔基体转运及其成熟,抑制NASH进展,是潜在治疗靶点。

研究设计与样本

  • 获取NASH患者及对照肝组织评估ARRB1表达;在Arrb1敲除与野生型小鼠中,分别以高脂饮食26周或MCD饮食6周建立NASH模型。

主要发现

  • NASH患者肝样本及小鼠NASH模型中ARRB1表达降低。
  • Arrb1缺失加速高脂饮食或MCD饮食小鼠的脂肪性肝炎发展,伴脂生成基因上调和β氧化基因下调。
  • ARRB1与GDF15相互作用并促进GDF15前体向高尔基体转运以进行切割和成熟。
  • 重组GDF15在体外和体内均消除Arrb1缺失下的脂质积累。
  • 在NASH模型中重新表达Arrb1可改善肝病,且过表达pro-GDF15时效果更显著;Arrb1缺失小鼠中单独过表达pro-GDF15的效果受损。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Non-alcoholic steatohepatitis (NASH) is associated with the dysregulation of lipid metabolism and hepatic inflammation. The causal mechanism underlying NASH is not fully elucidated. This study investigated the role of β-Arrestin1 (ARRB1) in the progression of NASH. METHODS: Liver tissue from patients with NASH and controls were obtained to evaluate ARRB1 expression. NASH models were established in Arrb1-knockout and wild-type mice fed either a high-fat diet (HFD) for 26 weeks or a methionine/choline-deficient (MCD) diet for 6 weeks. RESULTS: ARRB1 expression was reduced in liver samples from patients with NASH. Reduced Arrb1 levels were also detected in murine NASH models. Arrb1 deficiency accelerated steatohepatitis development in HFD-/MCD-fed mice (accompanied by the upregulation of lipogenic genes and downregulation of β-oxidative genes). Intriguingly, ARRB1 was found to interact with growth differentiation factor 15 (GDF15) and facilitated the transportation of GDF15 precursor (pro-GDF15) to the Golgi apparatus for cleavage and maturation. Treatment with recombinant GDF15 ablated the lipid accumulation in the presence of Arrb1 deletion both in vitro and in vivo. Re-expression of Arrb1 in the NASH models ameliorated the liver disease, and this effect was greater in the presence of pro-GDF15 overexpression. By contrast, the effect of pro-GDF15 overexpression alone was impaired in Arrb1-deficient mice. In addition, the severity of liver disease in patients with NASH was negatively correlated with ARRB1 expression. CONCLUSION: ARRB1 acts as a vital regulator in the development of NASH by facilitating the translocation of GDF15 to the Golgi apparatus and its subsequent maturation. Thus, ARRB1 is a potential therapeutic target for the treatment of NASH. LAY SUMMARY: Non-alcoholic steatohepatitis (NASH) is associated with the progressive dysfunction of lipid metabolism and a consequent inflammatory response. Decreased ARRB1 is observed in patients with NASH and murine NASH models. Re-expression of Arrb1 in the murine NASH model ameliorated liver disease, an effect which was more pronounced in the presence of pro-GDF15 overexpression, highlighting a promising strategy for NASH therapy.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Zhang Z, Xu X, Tian W, et al. ARRB1 inhibits non-alcoholic steatohepatitis progression by promoting GDF15 maturation. J Hepatol. 2019. PMID: 31857195. doi:10.1016/j.jhep.2019.12.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。